Figure 4From: Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patientsHER2 expression on the tumor infiltrated immune cells of HER2+ breast cancer patients. A Representative immunofluorescence staining of CD14+/HER2+ cells (HER2-trogocytosis) in HER2+ breast cancer tissues. Green arrow, CD14+ cells; red arrow, HER2+ cells; white arrow, CD14+/HER2+ cells. B Representative immunohistochemical staining of HER2 in HER2+ breast cancer tissues before systemic treatment. Black arrows indicate HER2+ tumor infiltrated immune cells. C Correlation between HER2-trogocytosis and a pathological complete response (pCR) in 13 HER2+ breast cancer patients treated with trastuzumab-based primary systemic therapy (P < 0.05).Back to article page